JP2019516104A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516104A5
JP2019516104A5 JP2018557905A JP2018557905A JP2019516104A5 JP 2019516104 A5 JP2019516104 A5 JP 2019516104A5 JP 2018557905 A JP2018557905 A JP 2018557905A JP 2018557905 A JP2018557905 A JP 2018557905A JP 2019516104 A5 JP2019516104 A5 JP 2019516104A5
Authority
JP
Japan
Prior art keywords
ldha
expression level
protein
mmp9
cadh1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557905A
Other languages
English (en)
Japanese (ja)
Other versions
JP7240712B2 (ja
JP2019516104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/057635 external-priority patent/WO2017190896A1/en
Publication of JP2019516104A publication Critical patent/JP2019516104A/ja
Publication of JP2019516104A5 publication Critical patent/JP2019516104A5/ja
Priority to JP2023003700A priority Critical patent/JP7492287B2/ja
Application granted granted Critical
Publication of JP7240712B2 publication Critical patent/JP7240712B2/ja
Priority to JP2024077227A priority patent/JP7797770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557905A 2016-05-04 2017-03-30 子宮内膜がんのマーカーとしてのperm Active JP7240712B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023003700A JP7492287B2 (ja) 2016-05-04 2023-01-13 子宮内膜がんのマーカーとしてのmmp9
JP2024077227A JP7797770B2 (ja) 2016-05-04 2024-05-10 子宮内膜がんのマーカーとしてのkpym

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168328 2016-05-04
EP16168328.9 2016-05-04
PCT/EP2017/057635 WO2017190896A1 (en) 2016-05-04 2017-03-30 Mmp9 as marker of endometrial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003700A Division JP7492287B2 (ja) 2016-05-04 2023-01-13 子宮内膜がんのマーカーとしてのmmp9

Publications (3)

Publication Number Publication Date
JP2019516104A JP2019516104A (ja) 2019-06-13
JP2019516104A5 true JP2019516104A5 (https=) 2020-04-23
JP7240712B2 JP7240712B2 (ja) 2023-03-16

Family

ID=56096908

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018557905A Active JP7240712B2 (ja) 2016-05-04 2017-03-30 子宮内膜がんのマーカーとしてのperm
JP2023003700A Active JP7492287B2 (ja) 2016-05-04 2023-01-13 子宮内膜がんのマーカーとしてのmmp9
JP2024077227A Active JP7797770B2 (ja) 2016-05-04 2024-05-10 子宮内膜がんのマーカーとしてのkpym

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023003700A Active JP7492287B2 (ja) 2016-05-04 2023-01-13 子宮内膜がんのマーカーとしてのmmp9
JP2024077227A Active JP7797770B2 (ja) 2016-05-04 2024-05-10 子宮内膜がんのマーカーとしてのkpym

Country Status (11)

Country Link
US (2) US20190137499A1 (https=)
EP (3) EP3452829B1 (https=)
JP (3) JP7240712B2 (https=)
AU (3) AU2017260806B9 (https=)
CA (2) CA3286798A1 (https=)
DK (1) DK3452829T3 (https=)
ES (1) ES2974307T3 (https=)
FI (1) FI3452829T3 (https=)
PL (1) PL3452829T3 (https=)
PT (1) PT3452829T (https=)
WO (1) WO2017190896A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3655778T3 (fi) * 2017-07-21 2023-08-09 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Agriini endometriumsyövän markkerina
EP4373973A1 (en) 2021-07-23 2024-05-29 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Biomarkers for endometrial cancer
CN113493838B (zh) * 2021-09-06 2021-11-23 北京泱深生物信息技术有限公司 子宫内膜癌相关的标志分子及其在诊断子宫内膜癌中的应用
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
AUPO573697A0 (en) 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
AU2004303448A1 (en) * 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
WO2008003024A2 (en) 2006-06-28 2008-01-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
US9046522B2 (en) 2009-07-24 2015-06-02 Geadic Biotec, Aie Markers for endometrial cancer

Similar Documents

Publication Publication Date Title
López et al. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection
Galletti et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device
Sandri et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome
Yuan et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma
JP2019516104A5 (https=)
FI3655778T3 (fi) Agriini endometriumsyövän markkerina
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
HRP20190533T1 (hr) Postupak za otkrivanje nukleosoma koji sadrže nukleotide
Kazakov et al. Fibroadenoma and phyllodes tumors of anogenital mammary-like glands: a series of 13 neoplasms in 12 cases, including mammary-type juvenile fibroadenoma, fibroadenoma with lactation changes, and neurofibromatosis-associated pseudoangiomatous stromal hyperplasia with multinucleated giant cells
JP2019500582A5 (https=)
Kuhs et al. Characterization of human papillomavirus antibodies in individuals with head and neck cancer
Cha et al. EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma
Larque et al. p16INK4a overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas
Shiozaki et al. Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature
Honing et al. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy
DK2054443T3 (da) Antistoffer mod en epitop fra AGR2, assays og hybridomer
Hanna et al. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma
JP2018515071A5 (https=)
Takeda et al. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma
Viswanathan et al. Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens
Chen et al. GP73 is down-regulated in gastric cancer and associated with tumor differentiation
CN104535766B (zh) 外周血exosome来源的肝癌诊断和预后标志物及其应用
EP4180814A3 (en) Markers of endometrial cancer
JP2020512549A5 (https=)
JP2017524933A5 (https=)